Brief: Adagene Announces Clinical Trial Collaboration To Evaluate Anti-Ctla-4 Safebody® Adg126 In Combination With Roche’S Standard-Of-Care For First-Line Advanced Liver Cancer
16/12/2022 11:37
Dec 16 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ANNOUNCES CLINICAL TRIAL COLLABORATION TO EVALUATE
ANTI-CTLA-4 SAFEBODY® ADG126 IN COMBINATION WITH ROCHE’S
STANDARD-OF-CARE FOR FIRST-LINE ADVANCED LIVER CANCER
* ADAGENE INC - ADAGENE WILL RETAIN GLOBAL DEVELOPMENT AND
COMMERCIALIZATION RIGHTS TO ADG126
* ADAGENE INC- COLLABORATION WILL UTILIZE ROCHE'S
MORPHEUS-LIVER
PLATFORM FOR RAPID AND EFFICIENT COMBINATION DEVELOPMENT
* ADAGENE INC - ADDITIONAL FINANCIAL DETAILS OF
COLLABORATION WERE
NOT DISCLOSED
Source text for Eikon: ID:nGNX50Z6JD
Further company coverage: 978y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate